Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis
Pooled result · Change in Vo2peakResult — go to the resultWeighted mean difference −2.13 mL·kg-1·min-1 95% CI −2.76 to −1.50Authors' conclusion
Systemic anticancer treatment leads to substantial and sustained impairments in CRF.
Study context
- Population
- Cancer survivors receiving systemic anticancer treatment44 studies
- Comparison
- Before vs after systemic anticancer treatment; cancer survivors vs noncancer controls
- Noncancer controln = 1,923reference
- Outcome
- Change in cardiorespiratory fitness (CRF) (Vo2peak) from before to after systemic treatment
Methodological detailsmeta-regression
- Meta-regression
Pooled result
Change in Vo2peak
Weighted mean difference
−2.13 mL·kg-1·min-1
95% CI −2.76 to −1.50
Post-treatment vs Pre-treatment
weighted mean difference −2.13 mL·kg-1·min-1 (95% CI −2.76 to −1.50)
As reported in the abstract
Further pooled results
| Outcome | Weighted mean difference (mL·kg-1·min-1) (95% CI) | |
|---|---|---|
| Post-treatment Vo2peak, cancer survivors vs noncancer controls · median 2 years (range: 6 weeks to 12 years) post-therapy · 17 cross-sectional studies | −6.39 (−7.60 to −5.18) | |
| −10−505Difference, mL·kg-1·min-1 (linear scale) |
Change in Vo2peak by cancer type (esophagogastric, breast, colorectal)
- No significant differences between patient subgroups
Arteriovenous oxygen difference and Vo2peak (meta-regression)
- Reduced arteriovenous oxygen difference associated with lower Vo2peak, β
- 2.55 (95% CI: 2.05-3.06; P < 0.001)
Original publication
Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis. JACC CardioOncol. Published 14 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it